Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112799 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yun Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Receptors-Mediated Gene Regulation, School of Basic Medical Sciences, Henan University, Henan, PR China; Hebi Key Laboratory of Liv…. Hauptthemen laut MEDLINE: Rifampin, Receptors, Cytoplasmic and Nuclear, Mice, Inbred C57BL, Mice, Knockout. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Science and Technology Innovation Talents in Universities of Henan Province.
Abstract (Originalsprache)
Antituberculosis drugs induce pharmacologic cholestatic liver injury with long-term administration. Liver injury resulting from rifampicin is potentially related to the bile acid nuclear receptor Farnesoid X Receptor (FXR). To investigate this, cholestasis was induced in both wild-type (C57BL/6N) mice and FXR knockout (FXR-null) mice through administration of rifampicin (200 mg/kg) via gavage for 7 consecutive days. Compared with C57BL/6N mice, FXR-null mice exhibited more severe liver injury after rifampicin administration, characterized by enlarged liver size, elevated transaminases, and increased inflammation. Moreover, under rifampicin treatment, FXR knockout impairs lipid secretion and exacerbates hepatic steatosis. Significantly, the expression of metabolism molecules BSEP increased, while NTCP and CYP7A1 decreased following rifampicin administration in C57BL/6N mice, whereas these changes were absent in FXR knockout mice. Furthermore, rifampicin treatment in both C57BL/6N and FXR-null mice was associated with elevated c-Jun N-terminal kinase phosphorylation (p-JNK) levels, with a more pronounced elevation in FXR-null mice. Our study suggests that rifampicin-induced liver injury, steatosis, and cholestasis are associated with FXR dysfunction and altered bile acid metabolism, and that the JNK signaling pathway is partially implicated in this injury. Based on these results, we propose that FXR might be a novel therapeutic target for addressing drug-induced liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Receptors-Mediated Gene Regulation, School of Basic Medical Sciences, Henan University, Henan, PR China; Hebi Key Laboratory of Liver Disease, Hebi Key Laboratory of Cardiovascular Diseases, Hebi Key L…
- Key Laboratory of Receptors-Mediated Gene Regulation, School of Basic Medical Sciences, Henan University, Henan, PR China.
- Hebi Key Laboratory of Liver Disease, Hebi Key Laboratory of Cardiovascular Diseases, Hebi Key Laboratory of Energy Metabolism, People's Hospital of Hebi, Henan University, Henan, PR China.
- State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, PR China.
- Key Laboratory of Receptors-Mediated Gene Regulation, School of Basic Medical Sciences, Henan University, Henan, PR China; Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical…
Förderung
- Science and Technology Innovation Talents in Universities of Henan Province
Zitieren
APA
Zhou, Y., Li, M., Cao, Y., Chang, W., Jia, H., Wang, L., Xu, H., Wang, Y., Liu, P., & Chen, W. D. (2024). Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112799
Vancouver
Zhou Y, Li M, Cao Y, Chang W, Jia H, Wang L, et al. Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112799
BibTeX
@article{Zhou2024,
author = {Zhou, Yun and Li, Meijie and Cao, Yutong and Chang, Weihua and Jia, Hao and Wang, Longmei and Xu, Huimin and Wang, Yandong and Liu, Peng and Chen, Wei-Dong},
title = {Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112799}
}
EUVIMED